This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.03.062v1 48/6/1120    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Borden, W. B. Articles by Faxon, D. P. Search for Related Content PubMed PubMed Citation Articles by Borden, W. B. Articles by Faxon, D. P.

STATE-OF-THE-ART PAPER

Facilitated Percutaneous Coronary Intervention

Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois.

Manuscript received March 24, 2006; accepted March 30, 2006.

^_* Reprint requests and correspondence: Dr. David P. Faxon, Department of Medicine, Brigham and Women’s Hospital, Department of Medicine, 1620 Tremont Street, OBC-3-12P, Boston, Massachusetts 02120. (Email: dfaxon{at}partners.org).

The goal of the initial treatment for ST-segment elevation myocardial infarction is rapid and effective reperfusion. Randomized trials have demonstrated that primary angioplasty is preferred over thrombolysis if done in a timely manner and by an experienced team. However, due to many factors, performance of primary angioplasty within the goal of 90 min is often not possible. A combined strategy of immediate thrombolysis in the emergency room or in the ambulance followed by angioplasty theoretically could provide early reperfusion with subsequent angioplasty to insure complete reperfusion. Over 17 clinical trials have been reported. Compared with thrombolysis, facilitated angioplasty in the most recent trials has been shown to have a more favorable long-term outcome. Trials comparing facilitated angioplasty with full- or half-dose thrombolysis versus primary angioplasty have been far less favorable with the largest trial to date, the ASSENT (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention)-4 trial, demonstrating a worse outcome in the primary end point of death, congestive heart failure, or shock at 90 days. Pending the results of the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial, current data suggest that facilitated angioplasty does not offer any advantage over primary angioplasty and may be harmful.

Abbreviations and Acronyms   AHA/ACC = American Heart Association/American College of Cardiology   AMI = acute myocardial infarction   ECSG = European Cooperative Study Group   PCI = percutaneous coronary intervention   PTCA = percutaneous transluminal coronary angioplasty   STEMI = ST-segment elevation acute myocardial infarction   TNK = tenecteplase   t-PA = tissue plasminogen activator

This article has been cited by other articles:

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF]